476 related articles for article (PubMed ID: 19479670)
21. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
[TBL] [Abstract][Full Text] [Related]
22. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
[TBL] [Abstract][Full Text] [Related]
23. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
24. The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy.
Issa MM; Zasada W; Ward K; Hall JA; Petros JA; Ritenour CW; Goodman M; Kleinbaum D; Mandel J; Marshall FF
Cancer Detect Prev; 2006; 30(3):269-75. PubMed ID: 16844319
[TBL] [Abstract][Full Text] [Related]
25. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.
Ganzer R; Rogenhofer S; Walter B; Lunz JC; Schostak M; Wieland WF; Blana A
Eur Urol; 2008 Mar; 53(3):547-53. PubMed ID: 17662520
[TBL] [Abstract][Full Text] [Related]
26. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
[TBL] [Abstract][Full Text] [Related]
27. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
28. [Prostatic cancer developing after transurethral resection of the prostate for benign prostatic hyperplasia].
Tanaka Y; Aoyama H; Momose H; Ono T; Samma S; Tanaka N; Akiyama T; Tani Y; Masuda Y; Matsuki H; Tani M; Tanaka M
Hinyokika Kiyo; 2001 Jan; 47(1):11-4. PubMed ID: 11235214
[TBL] [Abstract][Full Text] [Related]
29. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
31. Serum soluble Fas level for detection and staging of prostate cancer.
Furuya Y; Fuse H; Masai M
Anticancer Res; 2001; 21(5):3595-8. PubMed ID: 11848529
[TBL] [Abstract][Full Text] [Related]
32. [Prostatic cancer in a young adult: a report of 2 cases].
Sasaki H; Miki J; Hasegawa T; Hasegawa N; Ikemoto I; Ohishi Y
Hinyokika Kiyo; 2004 Jan; 50(1):57-9. PubMed ID: 15032019
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen: a valuable clinical tool.
Oesterling JE
Oncology (Williston Park); 1991 Apr; 5(4):107-22; discussion 122, 125-6, 128. PubMed ID: 1714288
[TBL] [Abstract][Full Text] [Related]
34. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
[TBL] [Abstract][Full Text] [Related]
35. Free PSA/total PSA ratio increases the detection rate of prostate cancer in twelve-core biopsy.
Yokomizo Y; Miyoshi Y; Nakaigawa N; Makiyama K; Ogawa T; Yao M; Kubota Y; Uemura H
Urol Int; 2009; 82(3):280-5. PubMed ID: 19440014
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer.
Kato T; Suzuki H; Komiya A; Imamoto T; Naya Y; Tobe T; Ichikawa T
Int J Urol; 2006 Jul; 13(7):915-9. PubMed ID: 16882055
[TBL] [Abstract][Full Text] [Related]
37. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
[TBL] [Abstract][Full Text] [Related]
38. [PSA: the difficult position of general practitioners between patients and urologists].
Vincendeau S; Abi Moussa M; Manunta A; Patard JJ; Guillé F; Lobel B
Prog Urol; 2003 Apr; 13(2):252-5. PubMed ID: 12765060
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy.
Merrick GS; Gutman S; Andreini H; Taubenslag W; Lindert DL; Curtis R; Adamovich E; Anderson R; Allen Z; Butler W; Wallner K
Eur Urol; 2007 Sep; 52(3):715-23. PubMed ID: 17337114
[TBL] [Abstract][Full Text] [Related]
40. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer.
Kubota Y; Kamei S; Nakano M; Ehara H; Deguchi T; Tanaka O
Int J Urol; 2008 Apr; 15(4):322-6; discussion 327. PubMed ID: 18380820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
